Jurkat cells were labeled with 1 µM indicated polymer and incubated with PBMC at an effector to target ratio of 20:1 in a 4 h cytotoxicity assay. The best protection was seen with the Sia polymer while other sialylated ligands provided reduced though still significant inhibition.
Supplementary Figure 6. Glycopolymer protection from purified NK cell cytotoxicity
Jurkat cells were incubated with 1 µM polymer for 45 min at room temperature and mixed with purified NK cells at indicated effector to target ratios. The coculture was incubated for 4 h at 37 ºC in 5% CO 2 and cell death was quantified by propidium iodide staining in flow cytometry. Jurkat cells were treated with indicated polymer and Siglec-9-F c binding was assessed by labeling with secondary anti-humanFc-647 followed by flow cytometry. 
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Supplementary Figure 9 . Artificially crosslinking Siglec-7 does not affect cytotoxicity NK cells were incubated with 10 µg/mL of anti-Siglec-7 (6-434, non-function blocking) or isotype antibody at rt for 20 min. followed by addition of 20 µg/mL of goat anti-Ms F(ab') 2 . 1,2 NK cells with crosslinked Siglec-7 were then cocultured with K562 cells at the indicated effector:target ratios for 4 h and analyzed for cytotoxicity by flow cytometry. As shown, Siglec-7 crosslinking alone did not alter the NK cytotoxic profile.
Supplementary Figure 10. Siglec-7 overexpression promotes Sia polymer inhibition
NK-92 cells overexpressing Siglec-7 showed inhibited cytotoxicity against Sia polymer coated Jurkat cells. Mock treated or Siglec-9 overexpressing cells show insiginficant difference in killing, though killing was overall depressed with Siglec-9 overexpression. Data are presented as mean ± s.d. from three independent experiments (*P < 0.05, **P < 0.01 for polymer coated versus no polymer control, two-tailed, paired analysis; n.s. not significant). n.s.
Siglec-7
Siglec-9 mock Sia Polymer
Supplementary Figure 11. Glycopolymers recover sialic acid-based cancer immunoprotection
Removal of cell surface sialic acid from WiDr colon, HepG2 hepatocarcinoma, Jurkat T lymphoma and H9 cutaneous T lymphoma cell lines increases susceptibility to NK cell cytotoxicity and is recovered by treatment with the sialic acid polymer (SiaPol). Cancer target cells were treated with VC sialidase for 1 h at 37 ºC before polymer incorporation at room temperature and coculture with purified NK (5:1, effector:target) in a 4 h cytotoxicity assay. Data are presented as mean ± s.e.m. from three independent experiments (*P < 0.05, **P < 0.01, for polymer coated versus no polymer control, twotailed, paired analysis). Purified NK cells were preincubated with 10 µg/mL of Siglec-7-blocking or isotype antibody and mixed with HL-60 cells at a 5:1 NK cell to target ratio in a 4 h cytotoxicity assay. The Siglec-7 blocking antibody significantly decreased the effects of sialidase anf polymer treatment (**P < 0.01, for sialidase treated versus no treatment control or Sia polymer coated versus sialidase treated, two-tailed, paired analysis; n.s. not significant).
Supplementary Figure 15. Siglec-7 expression is necessary for sialic acid dependent protection from NK-92 cell killing
NK-92 cells overexpressing FLAG-tagged Siglec-7 were cocultured with HL-60 cells at an 8:1 NK cell to target ratio. Only NK-92 cells expressing Siglec-7 were susceptible to sialylation dependent inhibition while mock treated cells were not affected (**P < 0.01, for sialidase treated versus no treatment control or Sia polymer coated versus sialidase treated, two-tailed, paired analysis; n.s. not significant). 
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Supplementary Figure 16. Sialic acid polymer inhibits HER2 ADCC of SK-BR-3
Cell surface sialic acid could also dampen NK-mediated ADCC against SK-BR-3 breast adenocarcinoma cells. Cytotoxicity assays were performed in the presence of 2 µg/mL anti-HER2 antibody in increasing NK:target ratios. Data are presented as mean ± s.d. from three independent experiments (*P < 0.05, **P < 0.01 for polymer coated versus no polymer control, two-tailed, paired analysis). 
Supplementary Note 1
Additional Synthetic Methods
General materials
Synthetic reagents were purchased from Sigma-Aldrich, Acros, and TCI and used without purification unless noted otherwise. Anhydrous DMF and MeOH, 99.9% purity were purchased from Acros in sealed bottles; all other anhydrous solvents (Fisher brand; HPLC grade) were obtained from an alumina column solvent purification system. EZ-Link Alkoxyamine-PEG4-Biotin (AO-biotin) was purchased from Pierce/Thermo Scientific. All reactions were carried out in flame-dried glassware under N 2 unless otherwise noted. In all cases, solvent was removed by reduced pressure with a Buchi Rotovapor R-114 equipped with a Welch self-cleaning dry vacuum. Products were further dried by reduced pressure with an Edwards RV3 high vacuum. Lyophilization was performed on a LABCONCO FreeZone instrument equipped with an Edwards RV2 pump. Thin layer chromatography was performed with Silicycle 60 Å silica gel plates and detected by UV lamp or charring with p-anisaldehyde in acidic EtOH. Flash chromatography was performed using Silicycle 60 Å 230-400 mesh silica. All 1 H and 13 C NMR spectra are reported in ppm and referenced to solvent peaks. NMR spectra were obtained on Bruker AVQ-400, DRX-500, AV-500, or AV-600 instruments. Size exclusion chromatography (SEC) was performed using a Viscotek TDA 302 SEC fitted with a Shodex SB-803 HQ column with differential refractive index detection. High resolution electrospray ionization (ESI) mass spectra were obtained from the UC Berkeley Mass Spectrometry Facility using an LTQ Orbitrap (Thermo Fisher Scientific).
Synthetic procedures and analytical data for new aminooxy compounds.
Aminooxy 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonate (11).
To the known protected precursor 3 O-[Methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonate] N-hydroxysuccinimide (210 mg, 0.36 mmol) in 4 mL anhydrous MeOH was added hydrazine hydrate (26 µL, 0.54 mmol) dropwise at 4 ºC and warmed to room temperature over 4 h. The reaction mixture was diluted with CH 2 Cl 2 and concentrated under reduced pressure. The crude residue was purified by silica chromatography (1%-20% MeOH/CH 2 Cl 2 ) to give the protected neuraminic acid with the free amniooxy (117 mg, 64%). The intermediate was dissolved in 3 mL anhydrous MeOH and NaOMe (25% in MeOH, 103 µL) was added dropwise while stirring at rt for 1 h followed by the addition of NaOH (1 M, 300 µL). After an additional 1 h, the reaction was neutralized with AcOH and stirred overnight at room temperature to complete hydrolysis. The resulting product was concentrated under vacuum and purified by silica column chromatography (4:2:1 EtOAc/MeOH/H 2 O). The desired fractions were pooled and concentrated under vacuum. The purified product was then dissolved in ddH 2 O and lyophilized to give the free aminooxy sialic acid 11 (49 mg, 65%) as an off-white powder. 1 
N-hydroxypent-4-eneamide (5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2→8)-α-(5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2→3)-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside (12).
N-Pentenoyl aminooxy 2,3-sialyllactose 4 (19 mg, 0.025 mmol), N-acetyl mannosamine (8.4 mg, 0.038 mmol), sodium pyruvate (14 mg, 0.127 mmol), and CTP•Na (21 mg, 0.038 mmol) were combined and dissolved in H 2 O (3 mL). A concentrated stock of Tris-HCl buffer pH 8.5 with MgCl 2 was added to a final concentration of 100 mM Tris, 20 mM MgCl 2 . Recombinant E. coli K12 sialic acid aldolase (2.5 U), N. meningitidis CMP-sialic acid synthetase (2.5 U), and C. jejuni α-2,8-sialyltransferase CstII (3 U) were added followed by H 2 O to bring the volume to 4 mL. The reaction mixture was incubated at 37 ºC for 4 h followed by shaking at rt for 16 h. The reaction was monitored by TLC (4:2:1 EtOAc/MeOH/H 2 O) and upon consumption of the starting material calf alkaline phosphatase was added to remove remaining nucleotide phosphate. After further incubation at 37 ºC for 1 h, the reaction mixture was quenched with cold MeOH (4 mL) and incubated on ice 15 min. The mixture was centrifuged, the precipitates were removed, and solution was concentrated under vacuum. The resulting residue was passed through a BioGel P-2 size exclusion column and eluted with water to obtain 12 (22 mg, 85%) as a white, fluffy powder after lyophilization. . After 1 h, MeONH 2 (53 mg, 0.64 mmol) was added to ensure complete deprotection and heated to 38 ºC for 2 h after which the reaction was quenched by the addition of 50 mM Na 2 S 2 O 3 in H 2 O until the solution became clear. The solvent was removed and the remaining residue was passed through a short silica chromatography column (EtOAc/MeOH/H 2 O). The desired fractions were pooled and concentrated. The material was further purified on a BioGel P-2 size exclusion column and lyophilized to give the free aminooxy GD3 13 (7.5 mg, 63%) as a white powder. 
Synthetic procedures and analytical data for glycopolymers.
Dipalmitoylphosphatidylethanolamine-poly(methyl vinyl ketone) (DPPE-PolyMVK) (1).
DPPE-Poly(MVK) was synthesized as previously described. 51 N,N-diisopropylethylamine (15 µL, 0.070 mmol) and the pentafluorophenyl activated ester of 4,4'-azobis(4-cyanovaleric acid) (ACVA-PFP) 51 (15 mg, 0.016 mmol) were added to a solution of DPPE (40 mg, 0.036 mmol) in MeOH (1.5 mL) and CHCl 3 (3.5 mL). After stirring at room temperature for 2 h, the resulting phospholipid initiator was concentrated by rotary evaporation. The resulting oil was suspended in anhydrous toluene (750 µL) and methyl vinyl ketone (210 µL, 2.5 mmol) was added followed by degassing with four freeze-pump-thaw cycles. The solution was heated to 80 ºC for 20 h and upon cooling to room temperature the polymer product was dissolved in minimal p-dioxane (3 mL) and triturated by dropwise addition to excess diethyl ether (300 mL). The precipitate was isolated by centrifugation (3,700×g, 20 min), washed with diethyl ether, and dried under vacuum to afford DPPE-PolyMVK as an off-white solid (110 mg). Spectral properties matched those previously reported. Aminooxy Glycan-Conjugated Polymers. All aminooxy compounds were conjugated to the DPPE-PolyMVK backbone by the following method: A mixture of 1 (1 equiv.), aminooxy compound (1.4 equiv. to ketone), and formic acid (1% v/v) in MeCN/MeOH (2:1, v/v) was stirred at 50 ºC for 20 h. To the reaction mixture was added H 2 O (to 25% v/v) and stirring was continued at 32 ºC for 18 h. For biotin and AF488 labeling, AO-biotin and AO-AF488 were added to the initial reaction mixture at 0.01 equivalents. After completion, the reaction was diluted in H 2 O and MeOH and concentrated under vacuum. The resulting residue was dissolved in H 2 O and dialyzed against aqueous 5mM NH 4 HCO 3 thrice and H 2 O once over 72 h to afford the corresponding oxime phospholipid polymer after lyophilization. Conversion was estimated by comparing the integration
